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ABSTRACT
Objective: To develop and externally validate risk
prediction equations to estimate the 10-year risk of heart
failure in patients with diabetes, aged 25–84 years.
Design: Cohort study using routinely collected data from
general practices in England between 1998 and 2014
contributing to the QResearch and Clinical Research
Practice Datalink (CPRD) databases.
Setting:We used 763 QResearch practices to develop
the equations. We validated it in 254 different QResearch
practices and 357 CPRD practices.
Participants: 437 806 patients in the derivation cohort;
137 028 in the QResearch validation cohort, and 197 905
in the CPRD validation cohort.
Measurement: Incident diagnosis of heart failure
recorded on the patients’ linked electronic General
Practitioner (GP), mortality, or hospital record. Risk
factors included age, body mass index (BMI), systolic
blood pressure, cholesterol/ high-density lipoprotein
(HDL) ratio, glycosylated haemoglobin (HbA1c), material
deprivation, ethnicity, smoking, diabetes duration, type of
diabetes, atrial fibrillation, cardiovascular disease, chronic
renal disease, and family history of premature coronary
heart disease.
Methods:We used Cox proportional hazards models to
derive separate risk equations in men and women for
evaluation at 10 years. Measures of calibration,
discrimination, and sensitivity were determined in 2
external validation cohorts.
Results:We identified 25 480 cases of heart failure in the
derivation cohort, 8189 in the QResearch validation
cohort, and 11 311 in the CPRD cohort. The equations
included: age, BMI, systolic blood pressure, cholesterol/
HDL ratio, HbA1c, material deprivation, ethnicity, smoking,
duration and type of diabetes, atrial fibrillation,
cardiovascular disease, and chronic renal disease. The
equations had good performance in CPRD for women (R2
of 41.2%; D statistic 1.71; and receiver operating
characteristic curve (ROC) statistic 0.78) and men (38.7%,
1.63; and 0.77 respectively).
Conclusions:We have developed and externally validated
risk prediction equations to quantify absolute risk of heart
failure in men and women with diabetes. These can be
used to identify patients at high risk of heart failure for
prevention or assessment of the disease.
INTRODUCTION
Cardiovascular disease is a major cause of
morbidity and decreased life expectancy in
patients with diabetes. Clinical guidelines
recommend cardiovascular risk assessment in
patients with diabetes1 2 to assist with preven-
tion of heart failure. Cardiovascular risk
assessment tools, including Framingham3
and QRISK2,4 are used both for communi-
cating risk to patients with diabetes and to
guide public health decisions.1 2
Considerable attention—in clinical trials,
guidelines and observational studies5—is
focused on predicting and preventing cardio-
vascular disease (particularly coronary heart
disease and stroke), reﬂecting perceptions
that it is the main disease burden for
diabetes.6 7
Less emphasis has been given to the devel-
opment of risk assessment methods to
predict heart failure among people with dia-
betes although it is recognised to be a sub-
stantial cause of morbidity and mortality
Strengths and limitations of this study
▪ The algorithms provide valid measures of abso-
lute risk of heart failure in patients with type 1 or
type 2 diabetes, as shown by the performance in
a separate validation cohort.
▪ Key strengths include size, duration of follow-up,
representativeness, and lack of selection, recall
and respondent bias.
▪ The study has good face validity since it has
been conducted in the setting where the majority
of patients in the UK are assessed, medically
treated, and followed up.
▪ The study used linked hospital and mortality data
records and is, therefore, likely to have picked up
the majority of heart failure diagnoses.
▪ The algorithms do not include some biomarkers
for heart failure, such as B-type natriuretic
peptide, as these are not routinely recorded in
electronic health records.
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requiring different investigations and treatments.6 8 9 It
is associated with signiﬁcant morbidity and healthcare
costs.8 Heart failure has also been associated as an
adverse event with selected antihyperglycaemic agents
used to treat diabetes.10 Once heart failure is present in
individuals with diabetes mellitus, there is a 10-fold
increase in mortality and a 5-year survival of only 12.5%,
a prognosis worse than metastatic breast cancer.11
We have developed and validated various risk predic-
tion equations, including QRISK24 for cardiovascular
disease, and QStroke12 for stroke, designed to quantify
an individual’s absolute risk of these clinically important
outcomes based on risk factors recorded in linked elec-
tronic health records. These risk equations are used
internationally in patients with and without diabetes to
assist in decisions regarding further investigation, treat-
ment or referral. While there have been several risk
scores to predict incident heart failure applicable to
patients with diabetes,9 13 14 these are not based on con-
temporaneous ethnically diverse populations, only cover
limited age ranges (eg, 45–64 years) or time periods,13
include very few patients with diabetes,13 or are limited
only to small numbers of patients with hospitalisations
for heart failure.9 None are currently in widespread use
for everyday clinical practice in the UK.
The objective of the present study is to derive and exter-
nally validate new risk prediction equations to quantify
10-year absolute risk of heart failure in patients with dia-
betes by using linked electronic health records. The
purpose of the equations is to better quantify absolute risk
of heart failure in order to prompt (1) closer management
of modiﬁable risk factors, (2) earlier diagnosis of heart
failure in ‘at risk’ patients, and (3) to provide better infor-
mation for patients and doctors to inform treatment deci-
sions about antihyperglycaemic agents which might also
inadvertently increase risk of heart failure.
METHODS
Study design and data source
We undertook a cohort study to derive and validate the
risk equations in a large population of primary care
patients using the large QResearch primary care data-
base (V.39, http://www.qresearch.org). QResearch is a
continually updated patient-level pseudonymised data-
base with event-level data extending back to 1989.
QResearch includes clinical and demographic data from
over 1000 general practices covering a population of >20
million patients, collected in the course of routine
healthcare by general practitioners and associated staff.
The primary care data includes demographic informa-
tion, diagnoses, prescriptions, referrals, laboratory
results and clinical values. Diagnoses are recorded using
the Read code classiﬁcation. QResearch has been used
for a wide range of clinical research including the devel-
opment and validation of risk prediction models.12 15
The primary care data is linked at individual patient
level to Hospital Episode Statistics (HES), and mortality
records from the Ofﬁce for National Statistics (ONS).
HES provides details of all National Health Service
(NHS) inpatient admissions since 1997, including
primary and secondary causes coded using the
International Classiﬁcation of Diseases, 10th Revision
(ICD-10) classiﬁcations. ONS provides details of all
deaths in England with primary and underlying causes,
also coded using the ICD-10 classiﬁcation. Patient
records are linked using a project-speciﬁc pseudony-
mised NHS number which is valid and complete for
99.8% of primary care patients, 99.9% for ONS mortality
records, and 98% for hospital admissions records.
We included all QResearch practices in England who
had been using their Egton Medical Information
Systems (EMIS) computer system for at least a year. We
randomly allocated three quarters of these practices to
the derivation data set and the remaining quarter to a
validation data set. In both data sets, we identiﬁed open
cohorts of patients aged 25–84 years registered with eli-
gible practices between 1 January 1998 and 31 July 2014.
We then selected patients with diabetes if they had a
Read code for diabetes or more than one prescription
for insulin or oral hypoglycaemics. We classiﬁed patients
as having type 1 diabetes if they had been diagnosed
under the age of 35 years and prescribed insulin.16 We
excluded patients without a postcode-related deprivation
score and patients with an existing diagnosis of heart
failure. We determined an entry date to the cohort for
each patient, which was the latest of the following dates:
25th birthday, date of registration with the practice plus
1 year, date on which the practice computer system was
installed plus 1 year, date of diagnosis of diabetes, and
the beginning of the study period (1 January 1998).
Patients were censored at the earliest date of the diagno-
sis of heart failure, death, de-registration with the prac-
tice, the last upload of computerised data, or the study
end date (1 August 2014).
We undertook a second external validation using
general practices in England contributing to the Clinical
Research Practice Datalink (CPRD). CPRD is a similar
database to QResearch except that it is derived from
practices using a different clinical computer system. We
used the subset of 357 CPRD practices which were
linked to ONS mortality and hospital admissions. We
used the same deﬁnitions for selecting a validation
cohort as done for QResearch except that the study end
date was 1 August 2012, the latest date for which linked
data were available.
Outcome
We classiﬁed patients as having incident heart failure if
there was a record of the relevant diagnosis either in their
primary care record, their linked hospital record, or mor-
tality record. We used Read codes to identify recorded clin-
ical diagnoses of heart failure from the primary care
record (G58%,G5yy9,G5yyA,662f,662g,662h,662i). We
used ICD-10 clinical codes (I110, I130, I42, I50) to identify
incident cases of heart failure from hospital and mortality
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records. We used the earliest recorded date of heart
failure on any of the three data sources as the index date
for the diagnosis of heart failure.
Predictor variables
We examined the following predictor variables based on
established risk factors for cardiovascular disease and
heart failure.14 15 17 18 We focused on variables likely to be
recorded as coded data in the patient’s electronic record.
For continuous variables, we used the closest values
recorded prior to the baseline date or within 6 months
after the cohort entry date. All other predictor variables
were based on the latest information recorded in the
primary care record before entry to the cohort. We did
not include natriuretic peptide levels since this is not rou-
tinely measured or recorded in electronic health records.
▸ Age at entry to cohort (continuous).
▸ Type of diabetes: type 1 or type 2.
▸ Number of years since diagnosis of diabetes (<1 year;
1–3; 4–6; 7–10 and ≥11 years).
▸ Smoking status (non-smoker; ex-smoker; light smoker
(1–9 cigarettes/day); moderate smoker (10–19 cigar-
ettes/day); heavy smoker (20+ cigarettes/day).
▸ Ethnic group (Caucasian/not recorded, Indian,
Pakistani, Bangladeshi, Other Asian, black Caribbean,
black African, Chinese, Other).15
▸ Townsend deprivation score (continuous)15 where a
higher score indicates greater levels of material
deprivation.
▸ Family history of premature coronary heart disease
(in a ﬁrst-degree relative aged less than 60 years).15
▸ Chronic renal disease19 (using Read codes for chronic
kidney disease (CKD) 4 or CKD5; nephrotic syndrome;
chronic glomerulonephritis; chronic pyelonephritis;
end-stage renal failure; renal transplant; dialysis).
▸ Cardiovascular disease (coronary artery disease or
cerebrovascular disease).19
▸ Atrial ﬁbrillation.15
▸ Treated hypertension.15
▸ Rheumatoid arthritis.15
▸ Body mass index (BMI) kg/m2(continuous).19
▸ Cholesterol/high-density lipoprotein (HDL) level
(continuous).15
▸ Systolic blood pressure (continuous).15
▸ Glycosylated haemoglobin (HbA1c) mmol/mol
(continuous).19 20
Derivation of the models
We developed the risk prediction equations in the deriv-
ation cohort using established methods.15 21 We used
fractional polynomials22 based on a complete case ana-
lysis to model non-linear risk relationships with continu-
ous variables (age, BMI, systolic blood pressure,
cholesterol/HDL ratio, HbA1c), where appropriate. We
used multiple imputation to replace missing values for
continuous values (BMI, systolic blood pressure, choles-
terol/HDL ratio, HbA1c) and smoking status, and used
these values in our main analyses.23 24 We carried out 10
imputations and included all of the candidate predictor
variables in the imputation model along with the
outcome variable and logarithm of person time. We used
Cox’s proportional hazards models to estimate the coefﬁ-
cients for each risk factor for men and women separately.
We used Rubin’s25 rules to combine the regression coefﬁ-
cients across the imputed data sets. We ﬁtted full models
initially then retained variables if these had a HR of <0.80
or >1.20 (for binary variables) and were statistically sig-
niﬁcant at the 0.05 level. We examined interactions
between predictor variables and age, and included these
where they were signiﬁcant, plausible, and improved
model ﬁt. We used regression coefﬁcients for each vari-
able from the ﬁnal model as weights which we combined
with the baseline survivor function evaluated up to
15 years to derive risk equations for over a period of
15 years of follow-up.26 This enabled us to derive risk esti-
mates for each year of follow-up, with a speciﬁc focus on
10-year risk estimates. We estimated the baseline survivor
function based on zero values of centred continuous vari-
ables, with all binary predictor values set to zero. Model
ﬁt was assessed by measuring the Akaike information cri-
terion (AIC) and Bayesian information criterion (BIC)
values for each imputed set of data.
Validation of the models
We used multiple imputation in the two validation
cohorts to replace missing values for continuous variables
and smoking status. We carried out 10 imputations and
included the candidate predictor variables in the imput-
ation model along with the outcome variable and the
logarithm of person time. We applied the risk equations
for men and women obtained from the derivation cohort
to the validation cohorts, and calculated measures of dis-
crimination. We calculated R2 values (explained variation
in time to diagnosis of heart failure27), D statistics28 (a
measure of discrimination where higher values indicate
better discrimination) and the area under the receiver
operating characteristic curve (ROC) statistic at 10 years,
and combined the model performance measures across
data sets using Rubin’s rules. We assessed calibration
using one imputed data set (comparing the mean pre-
dicted risks at 10 years with the observed risk by tenth of
predicted risk). The observed risks were obtained using
Kaplan-Meier estimates evaluated at 10 years. We applied
the equations to the validation cohorts to deﬁne thresh-
olds for the 10% of patients at highest estimated risk of
heart failure at 10 years.
We used all the available data on each database to
maximise the power and also generalisability of the
results. We used STATA (V.13.1) for all analyses. The
TRIPOD statement was adhered to in reporting.29
RESULTS
Overall study population
Overall, 1017 QResearch practices in England met our
practice inclusion criteria, of which 763 were randomly
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assigned to the derivation data set with the remaining
254 practices assigned to the validation cohort. We iden-
tiﬁed 455 551 patients aged 25–84 years with diabetes in
the derivation cohort. We excluded 976 patients
(0.21%) without a recorded Townsend deprivation score
and 16 769 (3.68%) with a diagnosis of heart failure at
baseline, leaving 437 806 for analysis.
We identiﬁed 142 718 patients aged 25–84 years with
diabetes in the QResearch validation cohort. We
excluded 299 patients (0.21%) without a recorded
Townsend deprivation score and 5391 (3.78%) with a
diagnosis of heart failure at baseline, leaving 137 028 for
validation.
We identiﬁed 206 050 patients aged 25–84 years with
diabetes in the CPRD validation cohort from the 357
practices with linked hospital and mortality data. We
excluded 8145 patients (3.95%) with a diagnosis of
heart failure at baseline, leaving 197 905 for validation.
Baseline characteristics
Table 1 shows baseline characteristics of 437 806 patients
with diabetes in the derivation cohort free from heart
failure at study entry. Of these, 412 556 (94.2%) had
type 2 diabetes and 25 250 (5.8%) had type 1 diabetes,
35.6% had been treated for hypertension, 17.4% had
cardiovascular disease, 1.0% had chronic renal disease,
and 3.2% had atrial ﬁbrillation. Just over half (54.2%)
had been diagnosed with diabetes for less than a year at
cohort entry, 17.0% had been diagnosed for 1–3 years,
9.4% for 4–6 years, 7.8% for 7–10 years, and 11.5% for
11 or more years before cohort entry. Smoking was
recorded in 95.3% of patients, ethnicity in 75.7%, BMI
in 90.8%, systolic blood pressure in 97.0%, HbA1c in
70.9% and cholesterol/HDL in 53.8%. Complete data
for all clinical values, smoking, and ethnicity were avail-
able for 182 477 (41.7%) of the derivation cohort.
Online supplementary table 1 shows the baseline
characteristics of the derivation cohort in men and
women separately. Online supplementary table 2 shows
the distribution of patients throughout the 10 geograph-
ical regions of England. Baseline characteristics for
patients in the QResearch validation cohort were similar
to corresponding values in the derivation cohort with
41.7% of patients having complete data for all clinical
values, smoking, and ethnicity. Baseline characteristics of
the CPRD validation cohort were also similar except that
the recording of ethnicity (45.0%) and HbA1c (58.1%)
was substantially lower in CPRD. In total, 19.4% of
CPRD patients had complete data for all candidate pre-
dictor variables.
Primary outcome of heart failure
Table 2 shows the number of incident cases of heart
failure during follow-up and the directly age standar-
dised incidence rates in each cohort. There were 25 480
cases of heart failure in the QResearch derivation
cohort, 8189 in the QResearch validation cohort, and
11 311 in the CPRD validation cohort.
Predictor variables
Table 3 shows adjusted HRs for variables in the ﬁnal
models for men and women in the derivation cohort
which included: age, BMI, systolic blood pressure, chol-
esterol/HDL, HbA1c, deprivation, duration and type of
diabetes, smoking status, ethnicity, atrial ﬁbrillation, car-
diovascular disease and chronic renal disease (the uni-
variate associations are shown in online supplementary
table 3). Increasing duration of diabetes was associated
with increased heart failure risk despite adjustment for
current age and other risk factors. Non-Caucasian
ethnic groups tended to have a lower risk of heart
failure compared with those whose ethnic group was
either Caucasian or not recorded. There was a ‘dose–
response’ relationship for smoking with heavy smokers
having the highest risk of heart failure. In women, type
1 diabetes had a 38% higher risk of heart failure com-
pared with type 2; atrial ﬁbrillation: 143% higher risk;
cardiovascular disease: 96% increased risk; and chronic
renal disease: 64% increased risk. The pattern was
similar for men. Figure 1 shows the adjusted HRs using
fractional polynomial terms for continuous variables.
Increasing age, BMI, systolic blood pressure, and HbA1c
were all associated with increasing HRs of heart failure.
The full equation for the model is published as open-
source software at http://qdiabetes.org/heart-failure/
index.php.
Validation
Discrimination
Table 4 shows the performance of each equation in each
validation cohort for women and men separately. In the
CPRD validation cohort, in women the algorithm
explained 41.2% of the variation in time to diagnosis of
heart failure (R2), and discrimination was good with a D
statistic of 1.71 and ROC value of 0.78. Corresponding
values for men were 38.72%, 1.63 and 0.77, respectively.
The results of the validation in the QResearch validation
cohort were very similar.
Calibration
Figure 2 shows the mean predicted risks and observed
risks of heart failure at 10 years—by tenth of predicted
risk—applying the equations to all men and women in
the QResearch and CPRD validation cohorts. There was
close correspondence between the mean predicted risks
and the observed risks within each model tenth in
women and men indicating that the equations were well
calibrated across both validation cohorts.
Performance at threshold for the 10% at highest risk
The sensitivity, speciﬁcity, and observed risk for the 10%
of women at highest predicted risk of heart failure in
the QResearch validation cohort (ie, cut-off for 10-year
risk of heart failure ≥21.8%) were 31.5%, 91.1%, and
32.0% respectively. The corresponding ﬁgures for men
(using a 10-year heart failure risk threshold of ≥ 23.9%)
were 30.6%, 91.2%, and 35.1%, respectively.
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Table 1 Baseline characteristics of patients with diabetes aged 25–84 years and without heart failure at baseline in the
QResearch derivation cohort and both validation cohorts
QResearch derivation
cohort (%)
QResearch validation
cohort (%)
CPRD validation
cohort (%)
Total number of patients without heart failure at baseline 437 806 (100) 137 028 (100) 197 905 (100)
Women 192 896 (44.1) 60 152 (43.9) 86 776 (43.8)
Men 244 910 (55.9) 76 876 (56.1) 111 129 (56.2)
Type 1 diabetes 25 250 (5.8) 7803 (5.7) 11 021 (5.6)
Type 2 diabetes 412 556 (94.2) 129 225 (94.3) 186 884 (94.4)
Diet control* 156 272 (35.7) 50 580 (36.9) 60 174 (32.2)
Oral hypoglycaemics only* 228 235 (52.1) 70 301 (51.3) 113 007 (60.5)
Oral hypoglycaemics+insulin* 399 (0.1) 105 (0.1) 197 (0.1)
Insulin only* 27 650 (6.3) 8239 (6.0) 13 506 (7.2)
Years since diagnosis of diabetes
<1 237 341 (54.2) 76 453 (55.8) 107 944 (54.5)
1–3 74 638 (17.0) 22 023 (16.1) 33 016 (16.7)
4–6 41 042 (9.4) 12 228 (8.9) 18 027 (9.1)
7–10 34 237 (7.8) 10 616 (7.7) 15 696 (7.9)
≥11 50 548 (11.5) 15 708 (11.5) 23 222 (11.7)
Mean age (SD) 60.0 (13.7) 60.4 (13.7) 61.0 (13.3)
Mean Townsend deprivation score (SD)† 0.6 (3.4) 0.2 (3.3) −0.2 (3.3)
Ethnicity
Ethnicity recorded 331 358 (75.7) 102 660 (74.9) 89 073 (45.0)
Ethnicity not recorded 106 448 (24.3) 34 368 (25.1) 110 519 (55.0)
Caucasian/not recorded‡ 363 702 (83.1) 118 727 (86.6) 184 564 (93.3)
Indian 15 534 (3.5) 4431 (3.2) 3468 (1.8)
Pakistani 10 513 (2.4) 1879 (1.4) 1552 (0.8)
Bangladeshi 12 444 (2.8) 1951 (1.4) 580 (0.3)
Other Asian 7072 (1.6) 2374 (1.7) 1920 (1.0)
Black Caribbean 9975 (2.3) 2797 (2.0) 1643 (0.8)
Black African 8357 (1.9) 2074 (1.5) 1718 (0.9)
Chinese 1396 (0.3) 409 (0.3) 305 (0.2)
Other 8813 (2.0) 2386 (1.7) 2155 (1.1)
Smoking status
Smoking status recorded 417 286 (95.3) 130 892 (95.5) 195 712 (98.9)
Non-smoker 219 640 (50.2) 67 736 (49.4) 81 393 (41.1)
Ex-smoker 118 560 (27.1) 38 750 (28.3) 39 936 (20.2)
Light smoker (1–9 cigarettes/day) 44 843 (10.2) 13 744 (10.0) 12 200 (6.2)
Moderate smoker (10–19 cigarettes/day) 17 943 (4.1) 5575 (4.1) 21 790 (11.0)
Heavy smoker (20+ cigarettes/day) 16 300 (3.7) 5087 (3.7) 16 801 (8.5)
Smoker amount not recorded 0 (0.0) 0 (0.0) 23 592 (11.9)
Family history and comorbidity
Family history of premature CHD 61 914 (14.1) 20 436 (14.9) 11 014 (5.6)
Rheumatoid arthritis 11 303 (2.6) 3440 (2.5) 2984 (1.5)
Atrial fibrillation 13 953 (3.2) 4593 (3.4) 6676 (3.4)
Cardiovascular disease 76 377 (17.4) 24 299 (17.7) 37 800 (19.1)
Treated hypertension 155 869 (35.6) 48 580 (35.5) 60 311 (30.5)
Chronic renal disease 4302 (1.0) 1352 (1.0) 1740 (0.9)
Clinical values
HbA1c recorded 310 356 (70.9) 96 061 (70.1) 114 920 (58.1)
Mean HbA1c mmol/mol (SD) 62.4 (21.5) 62.2 (21.5) 61.9 (21.7)
BMI recorded 397 409 (90.8) 124 129 (90.6) 183 301 (92.6)
Mean BMI, kg/m2 (SD) 30.3 (5.8) 30.4 (5.8) 30.2 (5.8)
Cholesterol/HDL ratio recorded 235 540 (53.8) 74 671 (54.5) 79 193 (40.0)
Mean cholesterol/HDL ratio (SD) 4.3 (1.4) 4.3 (1.4) 4.4 (1.6)
Systolic blood pressure recorded 424 623 (97.0) 133 157 (97.2) 194 340 (98.2)
Mean systolic blood pressure mm Hg (SD) 138.9 (19.2) 139.3 (19.2) 140.7 (19.7)
Values are numbers (percentages) unless stated otherwise.
*Per cent given are of all patients in total cohort.
†The Townsend score ranges between −8 and +11; increasing levels of Townsend scores indicate increasing levels of material deprivation.
‡Includes patients who were either recorded as Caucasian or those without any ethnicity recorded.
BMI, body mass index; CHD, coronary heart disease; HbA1c, glycosylated haemoglobin; HDL, high-density lipoprotein.
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The corresponding results for women on CPRD were
33.5%, 91.3% and 33.5%, respectively, and for men,
31.9%, 91.2% and 34.7%, respectively.
Figure 3 shows a clinical example of the implementa-
tion of the equation as a web calculator. For inter-
national users the postcode ﬁeld can be left blank.
Table 2 Numbers of incident cases of HF during follow-up and age standardised incidence rates per 1000 person years in
men and women with diabetes aged 25–84 years in the derivation cohort and validation cohorts
QResearch derivation cohort QResearch validation cohort CPRD validation cohort
Total HF
cases
Rate per 1000 person
years (95% CI)
Total HF
cases
Rate per 1000 person
years (95% CI)
Total HF
cases
Rate per 1000 person
years (95% CI)
Women 10 710 9.09 (8.92 to 9.26) 3395 8.99 (8.68 to 9.29) 4827 9.05 (8.79 to 9.31)
Men 14 770 11.66 (11.47 to 11.85) 4794 11.79 (11.46 to 12.12) 6484 11.44 (11.16 to 11.72)
Rates were directly age standardised to the overall age distribution of patients aged 25–84 years within the QResearch derivation cohort in
5-year age bands.
HF, heart failure.
Table 3 Adjusted HRs with 95% CIs for heart failure in men and women in the derivation cohort
Adjusted HR (95% CI)
Women* Men†
Age‡ 1.076 (1.074 to 1.079) 1.069 (1.067 to 1.071)
Cholesterol/HDL ratio‡ 1.04 (1.01 to 1.06) 1.03 (1.01 to 1.04)
Townsend deprivation score‡,§ 1.25 (1.21 to 1.28) 1.17 (1.14 to 1.20)
Duration of diabetes at baseline (years)
<1 1 1
1–3 1.45 (1.38 to 1.53) 1.29 (1.23 to 1.35)
4–6 1.53 (1.44 to 1.63) 1.47 (1.39 to 1.55)
7–10 1.72 (1.62 to 1.84) 1.49 (1.41 to 1.58)
≥11 1.94 (1.83 to 2.07) 1.72 (1.63 to 1.81)
Smoking status
Non-smoker 1 1
Ex-smoker 1.10 (1.05 to 1.15) 1.03 (0.99 to 1.07)
Light smoker (1–9 cigarettes/day) 1.33 (1.23 to 1.43) 1.34 (1.27 to 1.41)
Moderate smoker (10–19 cigarettes/day) 1.52 (1.38 to 1.69) 1.35 (1.23 to 1.48)
Heavy smoker (20+ cigarettes/day) 1.74 (1.55 to 1.95) 1.51 (1.38 to 1.66)
Ethnicity
Caucasian/not recorded 1 1
Indian 1.01 (0.89 to 1.16) 0.94 (0.84 to 1.05)
Pakistani 1.09 (0.92 to 1.29) 0.92 (0.80 to 1.06)
Bangladeshi 0.94 (0.78 to 1.13) 1.14 (1.00 to 1.30)
Other Asian 0.96 (0.76 to 1.22) 0.77 (0.63 to 0.95)
Black Caribbean 0.73 (0.64 to 0.83) 0.77 (0.68 to 0.88)
Black African 0.91 (0.72 to 1.16) 0.68 (0.53 to 0.87)
Chinese 0.78 (0.47 to 1.29) 0.41 (0.24 to 0.70)
Other ethnic group 0.82 (0.68 to 0.99) 0.74 (0.62 to 0.87)
Comorbidity
Type 1 diabetes¶ 1.38 (1.20 to 1.58) 1.19 (1.06 to 1.34)
Atrial fibrillation** 2.43 (2.27 to 2.60) 2.07 (1.95 to 2.19)
Cardiovascular disease** 1.96 (1.88 to 2.04) 2.19 (2.12 to 2.27)
Chronic renal disease** 1.64 (1.40 to 1.91) 1.77 (1.57 to 2.01)
For FP terms see footnotes and figure 1.
*Heart failure model in women included body mass index (2 FP terms −1 −.5), systolic blood pressure (2 FP terms −.5 0), hba1c (2 FP
terms −2 −2).
†Heart failure model in men included body mass index (2 FP terms −2 0), systolic blood pressure (2 FP terms 0 .5), hba1c (2 FP
terms −2 −2).
‡Adjusted HR is per unit increase.
§The Townsend deprivation score ranges between −7 (most affluent) and +11 (most deprived).
¶Adjusted HR compared with type 2 diabetes.
**Adjusted HR compared with patients without the condition at baseline.
FP, fractional polynomial; HbA1c, glycosylated haemoglobin; HDL, high-density lipoprotein.
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DISCUSSION
Key findings
We have developed and externally validated risk predic-
tion equations to quantify absolute 10-year risk of heart
failure in men and women with either type 1 or type 2
diabetes. To the best of our knowledge, this is the ﬁrst
equation to predict 10-year risk of heart failure in men
and women with diabetes based on a very large repre-
sentative ethnically diverse contemporaneous popula-
tion. The equations include 13 variables: age, BMI,
systolic blood pressure, cholesterol/HDL ratio, HbA1c,
material deprivation, ethnicity, smoking, duration and
type of diabetes, atrial ﬁbrillation, cardiovascular disease
and chronic renal disease. The equations were well cali-
brated and had good discrimination with ROC values
exceeding 0.75 in both validation cohorts. The purpose
of the equation is to better quantify absolute risk of
heart failure in order to prompt (1) closer management
of modiﬁable risk factors, such as smoking status, systolic
blood pressure, BMI and cholesterol, using appropriate
interventions for lifestyle or with medication; (2) earlier
diagnosis and treatment of heart failure in ‘at risk’
patients and (3) to provide better information for
patients and doctors to inform the treatment decisions
about antihyperglycaemic agents which might also inad-
vertently increase risk of heart failure.
Comparisons with the literature
We included established risk factors in our equation and
demonstrated HRs similar in both magnitude and direc-
tion to those reported for heart failure elsewhere,19 14
which increases the clinical face validity of the equations.
Cardiovascular disease was associated with a twofold
increased risk of heart failure, as in the study of 6496
patients with diabetes by Nichols et al.19 Chronic renal
disease, increasing BMI, increasing systolic blood pres-
sure29 and HbA1c level,20 and a longer duration of dia-
betes were associated with higher risk of heart failure.19
Compared with the Atherosclerosis Risk in Communities
(ARIC) study based on 15 792 US patients aged
45–64 years with 1487 heart failure events14 and the
Figure 1 Graphs of the adjusted HRs for the fractional polynomial (FP) terms for age, body mass index (BMI), glycosylated
haemoglobin (HbA1c) and systolic blood pressure (SBP) in the derivation cohort.
Table 4 Performance of the equations in men and women in
QResearch validation cohort and CPRD validation cohort
Statistic
QResearch
validation cohort
Mean (95% CI)
CPRD
validation cohort
Mean (95% CI)
Women
D statistic 1.66 (1.60 to 1.72) 1.71 (1.66 to 1.76)
R2 39.77 (38.07 to 41.46) 41.15 (39.72 to 42.58)
ROC 0.770 (0.762 to 0.778) 0.783 (0.776 to 0.789)
Men
D statistic 1.67 (1.62 to 1.72) 1.63 (1.58 to 1.67)
R2 40.04 (38.54 to 41.53) 38.72 (37.44 to 40.00)
ROC 0.764 (0.757 to 0.771) 0.769 (0.763 to 0.775)
Discrimination is the ability of the risk prediction model to
differentiate between patients who experience an admission event
during the study and those who do not. This measure is quantified
by calculating the area under the ROC statistic; where a value of
0.5 represents chance and 1 represents perfect discrimination.
The D statistic is also a measure of discrimination which is
specific to censored survival data. As with the ROC, higher values
indicate better discrimination. R2 measures explained variation
and higher values indicate more variation is explained.
ROC, receiver operating characteristic curve.
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study of 7067 Hong Kong patients with 274 heart failure
events,9 we have included a much larger, more contem-
poraneous ethnically diverse population of patients with
either type 1 or type 2 diabetes and spanning a wider
age range. We have included additional predictors such
as atrial ﬁbrillation, chronic renal disease, and HbA1c
Figure 2 The mean predicted risks and observed risks of heart failure at 10 years, by tenth of predicted risk, applying the
equations to all men and women in the QResearch and Clinical Research Practice Datalink (CPRD) validation cohorts. Crosses
denote 10-year observed risk; triangles denote 10-year predicted risk.
Figure 3 Web calculator applied to an example patient.
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known to be associated with risk of heart failure. Our
ROC values were similar to those from ARIC,14 lower
than those reported from a study of patients from Hong
Kong9 but higher than that reported for the published
Framingham heart failure score.14
Methodological considerations
The methods used to derive and validate these models
are the same as for a range of other clinical risk
prediction tools derived from the QResearch
database.12 15 30–32 The strengths and limitations of the
approach have been discussed in detail,15 21 including
information on multiple imputation of missing data. In
summary, key strengths of these models include size, dur-
ation of follow-up, representativeness, and lack of selec-
tion, recall and respondent bias. UK general practices
have good levels of accuracy and completeness in record-
ing clinical diagnoses and prescribed medications.33 Our
database has linked hospital and mortality records for
nearly all patients and is, therefore, likely to have picked
up the majority of cases of diagnosed heart failure
thereby minimising ascertainment bias. We undertook
two validations, one using a separate set of practices and
patients contributing to QResearch, and the other using
a fully external set of practices contributing to CPRD.
The results of both validations were extremely similar,
which is consistent with previous validation studies
showing comparable performance using different popu-
lations.21 34 While we have derived and validated the
score using UK data sets, the score can be used inter-
nationally by leaving the postcode deprivation ﬁeld
blank (in which case a mean value would be substituted)
or by creating an equivalent measure to the Townsend
score for local use. Best practice would be to undertake
a validation using a relevant population before local use
to ensure good calibration in the applicable population.
Limitations of our study include the lack of formal
adjudication of diagnoses, and potential for bias due to
missing data. However, we think our ascertainment of
diagnosed heart failure is likely to be high given the com-
bination of the three linked data sources although we
may have missed clinically silent heart failure. We did not
include natriuretic peptide levels since this is not rou-
tinely measured or recorded in electronic health records.
We have not provided deﬁnite comment on what thresh-
old of absolute risk should be used to deﬁne a “high risk”
group as that would require (1) the balance of risks and
beneﬁts for individuals and (2) cost-effectiveness analyses
which are outside the scope of this study.
CONCLUSION
We have developed and validated a new risk prediction
equation to quantify the absolute risk of heart failure in
patients with type 1 or type 2 diabetes. It can be used to
identify patients with diabetes at high risk of heart
failure for further assessment and proactive treatment.
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